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Autophagy, a cellular pathway for the degradation of damaged organelles and proteins, has gained in-
creasing importance in human pulmonary diseases, both as a modulator of pathogenesis and as a po-
tential therapeutic target. In this pathway, cytosolic cargos are sequestered into autophagosomes, which
are delivered to the lysosomes where they are enzymatically degraded and then recycled as metabolic
precursors. Autophagy exerts an important effector function in the regulation of inﬂammation, and
immune system functions. Selective pathways for autophagic degradation of cargoes may have variable
signiﬁcance in disease pathogenesis. Among these, the autophagic clearance of bacteria (xenophagy) may
represent a crucial host defense mechanism in the pathogenesis of sepsis and inﬂammatory diseases. Our
recent studies indicate that the autophagic clearance of mitochondria, a potentially protective program,
may aggravate the pathogenesis of chronic obstructive pulmonary disease by activating cell death pro-
grams. We report similar ﬁndings with respect to the autophagic clearance of cilia components, which
can contribute to airways dysfunction in chronic lung disease. In certain diseases such as pulmonary
hypertension, autophagy may confer protection by modulating proliferation and cell death. In other
disorders, such as idiopathic pulmonary ﬁbrosis and cystic ﬁbrosis, impaired autophagy may contribute
to pathogenesis. In lung cancer, autophagy has multiple consequences by limiting carcinogenesis,
modulating therapeutic effectiveness, and promoting tumor cell survival. In this review we highlight the
multiple functions of autophagy and its selective autophagy subtypes that may be of signiﬁcance to the
pathogenesis of human disease, with an emphasis on lung disease and therapeutics.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Autophagy is an evolutionarily-conserved cellular program for
the turnover of organelles and proteins through a lysosome-de-
pendent degradation pathway [1]. In the most common form of
autophagy (also called macroautophagy), cytosolic materials are
sequestered into double-membrane compartments called autop-
hagosomes, which subsequently fuse to lysosomes where their
contents are enzymatically degraded [2]. Two additional subtypes
of autophagy, microautophagy and chaperone-mediated autop-
hagy, have been described elsewhere [3].
Emerging evidence suggests that autophagy exerts complex
functions in human diseases that may include both protective andB.V. This is an open access article
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ter).potentially deleterious processes. The known functions of autop-
hagy in the clearance of subcellular debris and in metabolic re-
cycling have led to its general association with detoxiﬁcation and
cellular adaptive or protective mechanisms [1,4]. Autophagy is
now widely recognized as a key regulator of innate and adaptive
immune mechanisms, the modulation of which may profoundly
impact the pathogenesis of disease [5]. Among those processes
affected by autophagy include the regulation of inﬂammation,
antigen presentation, and bacterial clearance [5]. Furthermore
autophagy participates in the maintenance of vital organelle po-
pulations such as mitochondria, whose dynamic equilibrium is
important for cellular bioenergetics and homeostasis [6,7]. In re-
cent years, it has become evident that the signaling mechanismsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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death programs such as apoptosis and necroptosis [8–11]. These
observations uncover a potentially deleterious side of autophagy
associated with cellular degeneration and cell death, which may
have signiﬁcance in the pathogenesis of disease [8–11]. Among
those diseases where elevated or impaired autophagy has been
implicated in the pathogenic process include infectious and in-
ﬂammatory diseases, metabolic diseases, cancer, neurodegenera-
tive diseases, and diseases of the heart, kidney, liver and lung [12–
15]. The complex actions of autophagy in disease suggests that the
autophagy pathway can serve as a therapeutic target to modulate
the outcome of disease, which represents an area of rapid current
development [2,13]. In this review, we will focus on the involve-
ment of autophagy speciﬁcally in diseases of the lung, with an
emphasis on molecular regulation, pathogenesis, and therapeutic
targeting.Molecular regulation of autophagy
The process of autophagy involves the intracellular rearrange-
ment of membrane components originating primarily from the en-
doplasmic reticulum (ER), and other subcellular membranes in-
cluding the endosome/Golgi system, plasma membrane, mitochon-
drial membrane, and mitochondria–ER contact sites [16–24]. Au-
tophagy proceeds through sequential steps that begin with the for-
mation of the phagophore or isolation membrane at a pre-Fig. 1. Sequence of the (Macro)-autophagy pathway. Autophagy proceeds through a s
autophagosomal site. The nascent autophagic membrane elongates to form a double-m
include a speciﬁc cellular substrate (e.g., damaged mitochondria or aggregated protein).
lysosome to form a single-membraned autolysosome. The autophagosomal cargo is then
include free amino acids, fatty acids, and nucleotides, are released to the cytoplasm b
pathways.autophagosomal site (PAS) (Fig. 1). The nascent autophagic mem-
brane elongates to form a double-membrane autophagosome which
captures a region of cytoplasm, or in the case of selective autophagy,
a speciﬁc cellular substrate (e.g., damaged mitochondria or ag-
gregated protein). Upon maturation, the autophagosome containing
the isolated cargo then fuses with the lysosome to form a single-
membrane compartment called the autolysosome. The autophago-
somal cargo is then degraded in this compartment by lysosomal acid
hydrolases and other degradative enzymes. The resulting degrada-
tion products which may include free amino acids, fatty acids, and
nucleotides, are released to the cytoplasm by the action of lysosomal
permeases, where they may be reutilized for anabolic pathways [1].
The initiation and execution of autophagy is regulated by a
number of autophagy-related (Atg) proteins that were originally
identiﬁed in yeast. The mammalian homologs (ATG) of these
proteins have been identiﬁed and constitute the core autophagy
machinery [25,26]. Autophagy responds to regulation by upstream
signals initiated by glucose or amino acid starvation, and con-
stitutes an adaptive response under these conditions [1]. The
major molecular regulators of autophagy in response to starvation
or energy depletion include the mammalian target of rapamycin
complex 1 (mTORC1) and the energy sensing, 5′-adenosine
monophosphate-regulated kinase (AMPK), respectively (Fig. 2).
The mammalian target of rapamycin (mTOR) pathway, which
suppresses autophagy during nutrient replete conditions, is acti-
vated by growth factors through the Class I phosphatidylinositol-
3-kinase (PI3K)/Akt-pathway [27]. In addition to mTOR protein,eries of steps that begin with the formation of the isolation membrane at a pre-
embrane autophagosome which encompasses a region of cytoplasm, which may
Upon maturation, the autophagosome containing the isolated cargo fuses with the
enzymatically degraded in this compartment. The degradation products which may
y the action of lysosomal permeases, where they may be reutilized for anabolic
Fig. 2. Molecular regulation of autophagy. Autophagy responds to negative regulation by growth factor stimuli that regulate the Class I phosphatidylinositol-3-kinase (PI3K/
AKT) pathway, which upregulates the mTOR pathway. mTOR resides in a macromolecular complex (mTORC1): this multi-protein complex is activated by nutrient associated
signals including amino acids and growth factors, and negatively regulates autophagy by interacting with the ULK1 complex. Autophagy also responds to regulation by
depletion of cellular energy charge through the increased activity of the 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK). In response to elevated AMP
levels, AMPK inactivates mTORC1 and activates ULK1, which can activate Beclin1 and promote the trafﬁcking of mATG9. The initiation of autophagosome formation is also
regulated by the autophagy protein Beclin 1 (Atg6). Beclin 1 associates with a macromolecular complex that includes hVps34, a class III phosphatidylinositol-3 kinase
(PI3KC3), p150, and ATG14L. The Beclin1 complex produces PI3P which recruits assessory factors in autophagosome formation, including WIPI2. Autophagosome elongation
requires two ubiquitin-like conjugation systems, the ATG5-12 conjugation system, and the ATG8 (LC3) conjugation system. Autophagy protein LC3-II remains associated with
the maturing autophagosome.
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(Raptor), mammalian lethal with SEC13 protein 8 (mLST8), and the
40-kDa proline-rich Akt/PKB substrate (PRAS40) [28]. Inhibition of
mTORC1 by starvation or rapamycin results in the activation of
autophagy, through de-repression of its substrate complex, the
uncoordinated 51-like kinase-1 (ULK1) complex, which consists of
ULK1, Atg13, FIP200/RB1CC1, and Atg101 [29–33]. AMPK, which is
upregulated by increasing AMP levels, downregulates mTORC1 by
phosphorylating Raptor, and also directly activates ULK1 [34,35].
Recent studies suggest that AMPK-dependent ULK1 phosphoryla-
tion regulates the trafﬁcking of mAtg9, a transmembrane protein
responsible for membrane vesicle delivery to the PAS [36].
Autophagy is also regulated by the Beclin1 complex, consisting
of Beclin1 (homolog of Atg6), the class III PI3K (PI3KC3/Vps34),
p150, and Atg14L or UVRAG [37,38]. A link between ULK1 and the
regulation of Beclin 1 complex through direct phosphorylation of
Vps34 has recently been described [39,40]. Beclin 1 complexes
interact with several additional inhibitory (e.g., Bcl-2, Bcl-XL) or
activating (e.g., Ambra 1) proteins [37]. Activation of the intrinsic
PI3KC3 activity of the Beclin 1 complex results in the generation of
phosphatidylinositol-3-phosphate (PI3P), which is required for the
formation of the autophagosome. PI3P recruits accessory protein
factors that include the double FYVE-containing protein-1 (DFCP1)
and WD-repeat protein interacting with phosphoinositides (WIPI)
proteins, which may exert crucial functions in autophagosomeassembly [29,41,42]. Recent studies also implicate soluble N-
ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) proteins as crucial determinants in membrane recruit-
ment and autophagosome assembly [43,44].
The elongation of the isolation membrane to form the mature
autophagosome requires two ubiquitin-like conjugation systems:
the ATG5–ATG12 conjugation system and the LC3/ATG8 conjuga-
tion system [45]. ATG5–ATG12 conjugates, in association with
ATG16L1, are required for autophagosome assembly. The ubiqui-
tin-like protein microtubule-associated protein-1 light chain 3
(LC3B) (homolog of yeast Atg8) acts an important mediator of
autophagosome formation [26]. The ATG4B endopeptidase cleaves
pro-LC3 to generate LC3B-I. In mammals, the conversion of LC3B-I
(unconjugated form) to its phosphatidylethanolamine (PE)-con-
jugated and membrane-associated form LC3B-II represents a cru-
cial step in autophagosome biogenesis [45,46]. LC3B-II remains
incorporated in the autophagosomal membrane until the autop-
hagosome–lysosome fusion step. During the late stages of autop-
hagy, LC3B-II associated with the outer autophagosome membrane
is recycled by ATG4B, whereas LC3B-II on the inner membrane is
degraded by lysosomal activity [26].
Selective autophagy
While autophagy can serve as a non-speciﬁc degradation
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speciﬁc subcellular targets in processes referred to as “selective
autophagy” [47,48]. The modiﬁcation of subcellular targets by
ubiquitination represents a universal signal for identiﬁcation of
selective autophagy substrates [49]. The selective targeting of au-
tophagy substrates to the autophagosome is assisted by cargo
adaptor proteins (e.g., p62SQSTM1) that can associate both with
ubiquitinated substrates and with ATG8 homologs at the autop-
hagosomal membrane through a specialized LIR (LC3-interacting
region) [50]. The turnover of mitochondria through selective au-
tophagy pathways is termed mitophagy[6,7]. The classical model
for the regulation of mitophagy involves the activation of the
mitochondrial kinase PINK1 which recruits the E3: ubiquitin ligase
Parkin to the mitochondria where it subsequently ubiquitinates
proteins on the outer mitochondrial membrane [6,7,51]. Recent
studies indicate that PINK1 directly phosphorylates ubiquitin, as a
prerequisite for Parkin activation [52,53]. The capacity of autop-
hagy to clear intracellular pathogens such as bacteria, viruses, and
parasites is collectively referred to as xenophagy[5], whereas the
selective autophagic degradation of protein aggregates is termed
aggrephagy[54]. We have recently described a novel pathway for
the selective autophagic degradation of cilia components, a pro-
cess we have termed ciliophagy[55]. Additional subtypes of se-
lective autophagy and their speciﬁc cargo adaptors have been re-
viewed elsewhere [56].Autophagy, oxidative stress, and inﬂammation
Oxidative cellular stress describes a condition whereby the me-
tabolic production of reactive oxygen species (ROS) supersede cel-
lular antioxidant capacity, leading to damage to cellular macro-
molecules such as DNA, lipids, and proteins [57]. Oxidative stress is
associated with the mitochondrial or enzymatic production of su-
peroxide anion radical (O2), and its dismutation product hydrogen
peroxide (H2O2). Production of these species may lead to the gen-
eration of additional reactive and deleterious species including the
hydroxyl radical and peroxynitrite [58]. The interrelationship be-
tween the activation of autophagy as a stress response, and the
propagation of cellular injury by oxidative stress has long been
proposed [59,60]. Experimental evidence with model compounds
such as H2O2 and respiratory chain inhibitors suggests that the au-
tophagy can be upregulated in response to oxidative stress [61–64].
Furthermore, we have demonstrated that autophagy can be acti-
vated by increasing or decreasing the ambient oxygen tension
[65,66]. Autophagy may represent a general cellular protective me-
chanism against oxidative stress, by acting as a degradative pathway
for oxidatively-modiﬁed substrates, including protein and phos-
pholipids [4,67]. The function of autophagy in mitochondrial
homeostasis may also be of critical importance during oxidative
stress, as mitochondria represent an intracellular source of ROS, as
well as a functional target for ROS generation [68].
The activation of autophagy by oxidative stress may be trig-
gered by accumulation of damaged substrates. However, limited
evidence suggests that components of the autophagy machinery
(i.e., ATG4B) may be subjected to direct redox regulation [64].
Furthermore, recent studies suggest a functional cross-talk be-
tween the regulation of the mammalian antioxidant response and
that of autophagy. Nuclear factor erythroid 2-related factor (Nrf2)
serves as a master regulator of cellular antioxidant defenses. Nrf2
dissociates from its cytoplasmic anchor, the Kelch-like ECH-asso-
ciated protein 1 (Keap-1) and binds to antioxidant response ele-
ments in promoters of genes critical for the antioxidant response
[69,70]. The autophagy cargo adaptor protein p62 has recently
been identiﬁed as an Nrf2-regulated gene [69]. p62 interacts with
and promotes the displacement of Keap-1 from Nrf2, and thusactivates Nrf2 transcriptional activity [71]. Keap1 is also con-
stitutively degraded by p62-dependent autophagy [72].
Autophagy has been implicated in the regulation of in-
ﬂammation, which is intimately linked to oxidative stress [56]. We
have identiﬁed an important function of autophagy in the ROS-
dependent regulation of the inﬂammasome signaling pathway in
activated macrophages [73]. Inﬂammasomes represent an in-
ﬂammatory signaling platform activated by infection or stress that
govern the maturation and secretion of pro-inﬂammatory cyto-
kines such as IL-1β and IL-18 [74]. Genetic deletion of autophagy
proteins (i.e., Beclin 1, LC3B) in primary macrophages caused en-
hancement of mitochondrial ROS generation, and promoted NOD-
like receptor family, pyrin domain containing 3 (NLRP3) in-
ﬂammasome activation in response to pro-inﬂammatory stimuli
[73,75]. Similar observations have been made in models of high fat
diet-induced metabolic disease, such that palmitate-induced dis-
ruption of mitophagy in macrophages was associated with in-
creased activation of the NLRP3 inﬂammasome [76].Autophagy in acute lung injury and sepsis
Acute lung injury (ALI) and sepsis continue to represent pri-
mary causes of morbidity and mortality during the management of
critically ill patients. Although relatively few studies have been
performed in this area, recent model studies from our group and
others have implicated autophagy as potentially important in the
pathogenesis of both ALI and sepsis [65,77,79] (Fig. 3).
High oxygen therapy (hyperoxia) is used in critical care settings
to maintain tissue oxygenation. ALI may occur as the result of
mechanical ventilation or hyperoxia treatments, the latter which
causes enhanced ROS production. Extended exposure to hyperoxia
(495% O2) is a highly reproducible model of ALI in mice, which
targets the pulmonary epithelium [78]. We have shown that hy-
peroxia exposure causes elevation of histological and biochemical
markers of autophagy in vivo, including autophagosome formation
and LC3B-II accumulation [65]. Studies of cultured pulmonary
epithelial cells, a primary target of hyperoxia in the lung, also in-
dicated that hyperoxia can activate LC3B conversion in vitro,
which was reversible by antioxidants [65]. Genetic interference of
the autophagosome-associated protein LC3B sensitized epithelial
cells to hyperoxia induced cell death and augmented the extrinsic
apoptosis pathway [65]. These results suggested that LC3B acts as
a pro-survival factor in oxygen-dependent cytotoxicity, and un-
derscore a potential cross-talk between autophagy and apoptosis
during oxygen toxicity [65].
We have recently demonstrated that mice subjected to cecal
ligation and puncture (CLP), a model of polymicrobial sepsis, dis-
play evidence for elevated autophagy in the lung tissue, including
increased LC3-II expression and accumulation of autophagosomes
[79]. Becn1þ / mice were susceptible to the lethal effects of CLP.
Becn1þ / mice displayed reduced bacterial clearance from the
blood and vital organs subsequent to CLP. Furthermore, Beclin
1 was required for the therapeutic effectiveness of carbon mon-
oxide, a candidate anti-inﬂammatory therapy, at alleviating mor-
tality and promoting bacterial clearance in this model [79]. We
concluded that Beclin 1 can signiﬁcantly contribute to sepsis sur-
vival by enhancing bacterial clearance [79]. Additional studies in
the Staphylococcus aureus sepsis model are suggestive of increased
mitophagy as a component of lung responses to inﬂammation. The
study noted decreased Beclin 1 protein and increased p62 accu-
mulation, suggestive of dysregulated autophagy, but observed in-
creased in LC3-II accumulation that colocalized with mitochondria,
suggestive of activated mitophagy [80].
Fig. 3. Signiﬁcance of autophagy in pulmonary disease. Autophagy may exert multiple functions that may be relevant to the pathogenesis of lung disease. These include the
general protective effects of autophagy in metabolic recycling, the regulation of inﬂammation, and the regulation of cell death pathways. The protective aspects of autophagy
against carcinogenesis in primary cells, may also provide a paradoxical survival advantage to growing tumors. In certain diseases such as ﬁbrotic lung diseases, impaired
autophagy may inﬂuence the pathogenesis. Specialized subtypes of selective autophagy may gain importance in select pulmonary disorders. The xenophagy function of
autophagy may be important in infectious diseases and sepsis. The mitophagy and ciliaphagy programs have recently been implicated in the pathogenesis of chronic lung
disease.
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An emerging role for autophagy as a central player in innate and
adaptive immune functions has recently emerged [5]. Autophagy
makes an important contribution to host defense against various
microbes including bacteria, viruses, and parasites [5,12,13]. The
anti-bacterial and anti-pathogenic functions of autophagy have been
widely demonstrated [81,82]. Phagocytosis of nonpathogenic my-
cobacteria by macrophages promotes autophagy and apoptosis,
which results in the elimination of the pathogen. However, phago-
cytosis of pathogenic mycobacteria can inhibit the autophagy
pathway [83]. Although of potential importance in many in-
ﬂammatory and infectious diseases, the relevance of autophagy in
respiratory infections will be discussed here.
Tuberculosis, the result of infection with the pathogen Myco-
bacterium tuberculosis (Mtb), is a major contributor to global dis-
ease burden [84]. During Mtb infection, the mycobacteria remains
and replicates in immature phagosomes. Mtb employs a strategy
for survival that involves interference with the fusion between
phagosomal compartments containing Mtb and lysosomes [85]. In
addition, instead of stimulating macrophage apoptosis, phagocy-
tosis of Mtb promotes necrotic cell death, which promotes bacteria
dispersal to uninfected cells. As a result, reduced mycobacterial
antigen presentation and chronic Mtb infection occur [86].
Therapeutic upregulation of autophagy can reduce intracellular
replication and survival of Mtb [81,82,86,87,88]. Severaltherapeutics that stimulate autophagy through mTORC1 inhibition
have been recently shown to be effective against Mtb infection
[89,90]. Conversely, chemical inhibitors of autophagy promote Mtb
infection [82].
Autophagic process may assist in the generation of anti-viru-
lence factors against Mtb, through degradation of substrate pro-
teins [91,92]. Interferon-gamma (IFN-γ) production acts as an
important host defense factor against Mtb. Macrophages stimu-
lated with IFN-γ induce autophagy, and this response facilitates
the resolution of infection [82,91]. IFN-γ stimulation can thereby
bypass the inhibition of lysosomal fusion of virus containing
phagosomes, leading to the degradation of the bacteria by p62-
dependent selective autophagy [91], and resolution of infection.
IFN-γ induced autophagy requires the p47 guanosine tripho-
sphatase IRGM-1 [82,93,94]. Small nucleotide polymorphisms oc-
curring in the IRGM-1 gene have been linked to increased sus-
ceptibility to Mtb infection [95].
Recent studies have identiﬁed a selective autophagy pathway
for Mtb processing [96]. The bacterial early secretory antigenic
target 6 (ESAT-6) system 1 (ESX-1) secretion system mediates
phagosomal permeabilization to permit the ubiquitin-mediated
autophagy pathway access to phagosomal Mtb. The stimulator of
interferon genes (STING)-dependent cytosolic pathway recognizes
extracellular bacterial DNA and tags bacteria with ubiquitin. Au-
tophagy cargo adaptors, p62 and NDP52, subsequently recognize
ubiquitinated Mtb and target them to autophagosomes.
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against other respiratory pathogens. Genetic deﬁciency of Atg9
promoted the growth of Legionella pneumophila, the causative
agent in Legionnaire’s disease, which suggests a role of autophagy
in defense against this organism [97]. Genetic deﬁciency of Atg7
sensitized mice to the lethal effects of Klebsiella pneumoniae in-
fection, involving increased bacterial counts, inﬂammation, and
lung injury [98]. Infection with inﬂuenza viruses (e.g., inﬂuenza-A)
can promote the induction of autophagy, and autophagosome
formation which is required for viral replication [99]. Inﬂuenza-A
proteins (e.g., M2 protein) may also inhibit autophagosome ma-
turation and fusion to the lysosome [100]. In the context of in-
ﬂuenza infections, recent studies have uncovered a new role for
autophagy in the maintenance of memory B cells, which are re-
quired for secondary antibody responses. Mice with B cell-speciﬁc
deletion of Atg7 displayed impaired secondary antibody responses,
and thereby higher sensitivity to inﬂuenza virus challenge [101]. In
conclusion, the development of therapeutic strategies involving
the modulation of the autophagy pathway to reduce infection and
promote adaptive immunity to infectious pathogens may be of
considerable interest.Autophagy in pulmonary vascular disease
Pulmonary arterial hypertension (PAH) is a serious disease af-
fecting the pulmonary vasculature, that is characterized by sus-
tained elevation of pulmonary arterial pressure (425 mm Hg at
rest) [102]. PAH is classiﬁed as a pulmonary-selective vascular
remodeling disease in which vascular smooth muscle cells display
a proliferative and anti-apoptotic phenotype [102]. Pulmonary
arterial remodeling occludes the vessel lumen that leads to right
ventricular failure and premature death [103]. We have recently
demonstrated an elevated incidence of autophagy in lung tissue
derived from patients with various forms of pulmonary hy-
pertension (PH), including PAH [66].
Pulmonary hypertension (PH) is a progressive and often fatal
complication of chronic lung disease [104]. Chronic hypoxia in-
duces pulmonary arterial vascular smooth muscle cell prolifera-
tion, which is a cause of vascular remodeling during PH [105]. In
the mouse model, chronic exposure to hypoxia caused increased
incidence of PH which was associated with increased autophago-
some formation in lung tissue. Autophagy deﬁcient, LC3B null
(Map1lc3B/) mice displayed heightened indices of PH after
exposure to chronic hypoxia compared to wild-type mice [66].
Furthermore, blockade of mTORC1, which induces autophagy, was
shown to exert anti-proliferative effects on pulmonary vascular
cells [106,107]. These results, taken together, suggest that stimu-
lation of autophagy or inhibition of the mTOR pathway may have
protective effects during the pathogenesis of PH.
In contrast, autophagy deﬁciency through the knockdown of
the autophagy protein Beclin 1 resulted in improved angiogenesis
in pulmonary artery endothelial cells from fetal lambs with per-
sistent pulmonary hypertension [108]. We have also demonstrated
increased angiogenesis in Beclin1 heterozygous knockout mice
subjected to hypoxia [109]. These results suggested that Beclin
1-dependent autophagy may contribute to the pathogenesis of PH.
In contrast, chloroquine, an inhibitor of autophagy, has been re-
ported to prevent progression of experimental PH [110]. The LC3
and mTOR pathway have recently been highlighted as potential
therapeutic targets in hypoxia-induced PH [111,112]. Due to con-
ﬂicting studies, the contribution of autophagy to the pathogenesis
of PH and related vascular disorders requires further investigation.Autophagy in idiopathic pulmonary ﬁbrosis
Fibrosis is characterized by the excessive extracellular matrix
protein deposition in the basement membrane and interstitial tissue
of an injured epithelium and expansion of activated mesenchymal
cells (i.e., myoﬁbroblasts) [113]. Lung ﬁbroblasts are important
components of the interstitium which are principal producers of
extracellular matrix as well as participate in wound healing. Defec-
tive ﬁbroblast autophagic processes have been implicated in the
pathogenesis of IPF. Lung tissues from IPF patients and human lung
ﬁbroblasts treated with TGF-β demonstrate increased cellular se-
nescence and decreased autophagic activity as characterized by
decreased LC3B protein expression [114,115]. TGF-β1 inhibits au-
tophagy in human lung ﬁbroblasts. Genetic deletion of the autop-
hagy proteins, LC3B or Beclin 1, potentiated the TGF-β1-induced
expression of ﬁbronectin and the myoﬁbroblast marker α-smooth
muscle actin in ﬁbroblasts [115]. Treatment of mice with the mTOR
inhibitor rapamycin, partially protected against lung ﬁbrosis [115].
Loss of autophagy in patients with IPF may potentiate the effects of
TGF-β1 with respect to extracellular matrix production and trans-
formation to a myoﬁbroblast phenotype. In a murine bleomycin
model of pulmonary ﬁbrosis, blockade of IL-17A in the lung was
shown to protect against ﬁbrosis in part by restoring autophagy
[116]. Further research is needed to determine the relationships
between autophagy and the molecular mechanisms of ﬁbrogenesis.Autophagy in cystic ﬁbrosis
Cystic ﬁbrosis (CF) is a fatal autosomal recessive disease which is
caused by mutation in the gene encoding the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR). CF is characterized by
accumulation of hyperviscous mucous, which obstructs the airways,
resulting in recurrent pulmonary infections. The most common CFTR
mutation is a deletion of phenylalanine at position 508 (CFTRF508del)
in the CFTR gene [117]. Recent studies have implicated CF as a dis-
ease involving impaired autophagy. Cells with CFTRF508del display
accumulated polyubiquitinated proteins, defective autophagy and
the decreased clearance of aggresomes [118]. Dysfunctional autop-
hagosome clearance in CF has also been shown to contribute to
heightened inﬂammatory responses [119]. Defective CFTR also re-
sults in increased ROS production and upregulation of tissue trans-
glutaminase [120]. These events were associated with the cross-
linking and inactivation of Beclin 1, leading to sequestration of
PI3KC3 and accumulation of p62 [120]. Restoration of Beclin 1 or
depletion of p62 rescued the trafﬁcking of mutant CFTR to the cell
surface [120]. Genetic targeting of p62 was also recently shown to
improve the therapeutic effect of CFTR channel activators [121].
The autophagic clearance of bacteria (xenophagy) may be im-
portant in defense against the secondary infections associated with
CF. Administration of the mTOR inhibitor rapamycin decreases Bur-
kholderia cenocepacia infection and reduces inﬂammation in the lungs
of CF mice [122]. Pharmacological enhancement of autophagy in vivo
also effectively promoted bacterial clearance of Pseudomonas aerugi-
nosa from the lung [123]. In conclusion, the impairment of autophagy,
and several of its selective autophagy subtypes may accelerate the
pathogenesis of CF. Functions of autophagy that may be compromised
in CF include bacterial clearance, protein aggregate processing, and
the maintenance of mitochondria. Thus, strategies aimed at the re-
storation of autophagy may have therapeutic potential in CF [124].Autophagy and mitophagy impact the pathogenesis of chronic
obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD), contributes
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clinical phenotypes of emphysema (loss of alveolar surface area)
and bronchitis associated with mucus obstruction of the airways
[126]. Cigarette smoke (CS) is the most common risk factor for
COPD [127]. The mechanisms underlying the pathogenesis of
COPD remain incompletely understood but implicate aberrant
inﬂammatory and cellular responses in the lung, lung vasculature,
and airways in response to CS [126,127]. Our recent studies have
evaluated the incidence of autophagy in the pathogenesis of COPD
by examining static autophagic markers in human lung tissue of
COPD patients. In COPD lung tissues we found an elevation of
general autophagy markers, such as the increased expression of
the autophagosomal marker LC3-II, and other ATG proteins, and
the increased occurrence of autophagosomes in situ [128]. To in-
vestigate the involvement of autophagy in the pathogenesis of
emphysema, we employed a model of emphysematous airspace
enlargement in mice subjected to chronic (6 months) CS exposure.
Lung tissue derived from mice chronically exposed to CS displayed
increased autophagosome numbers and increased expression of
autophagy proteins [128,129]. Autophagy-deﬁcient LC3B-null mice
(Map1lc3B/) were resistant to CS-induced airspace enlargement
during chronic CS exposure [129]. To investigate the involvement
of autophagy in the pathogenesis of bronchitis associated with
COPD, we employed a mouse model of mucociliary clearance
disruption in mice subjected to acute (3 weeks) CS exposure. We
found that autophagy-deﬁcient Map1lc3B / or Becn1þ / mice
were resistant to mucociliary clearance disruption in the airways
after subchronic CS exposure in vivo [55].
We have also identiﬁed a functional role for autophagic pro-
teins in CS-induced epithelial cell death [128,129]. In vitro studies
with cultured epithelial cells subjected to aqueous cigarette smoke
extract (CSE) responded with increased autophagosome formation
and accumulation of LC3B-II. CSE induced the extrinsic apoptosis
pathway in epithelial cells and downstream activation of pro-
apoptotic caspases. Genetic deletion of crucial autophagy proteins
(i.e., Beclin 1 or LC3B) inhibited apoptosis in response to CSE ex-
posure in vitro, suggesting that increased autophagy occurred in
association with epithelial cell death [128–130]. In mechanistic
studies, we described a potential cross-talk between LC3B and the
activation of extrinsic apoptosis in epithelial cells exposed to CSE
[129]. Following CSE stimulation, LC3B interacted with the death
receptor Fas, a component of the extrinsic apoptosis pathway, and
the lipid raft scaffold protein caveolin-1. These data underscore
complex interactions between the regulation of autophagy and
programmed cell death during CS exposure [129]. In conclusion,
autophagy modulation can be observed in lung macrophages,
bronchial and epithelial cells upon CS exposure and in the lungs of
COPD patients [128–130]. Our recent studies suggest that autop-
hagy promotes lung epithelial cell death, airway dysfunction, and
emphysema in response to CS exposure in vivo [55,128,129].
However, the underlying mechanisms remain to be elaborated.
In addition to the general autophagy pathway as we have de-
scribed, emerging studies suggest that selective autophagy may be
important in COPD pathogenesis. Increased accumulation of p62
and ubiquitinated proteins have been detected in lung homo-
genates from COPD patients and in human bronchial epithelial
cells exposed to CSE [131]. CS exposure may impair the delivery of
bacteria to lysosomes suggesting that defective xenophagy in al-
veolar macrophages of smokers may contribute to recurrent in-
fections [132]. Consistent with a detrimental role for the activation
of autophagy in chronic lung disease we have also recently de-
scribed a pro-pathogenic role for selective autophagic processes in
the pathogenesis of COPD [55,133].
We reported that ciliophagy, the selective autophagic de-
gradation of cilia, regulates cilia length during CS exposure [55].
Impaired airway clearance caused by cilia shortening, prevents theelimination of pathogens from the airways and may cause re-
current respiratory infections. We demonstrated that autophagy-
deﬁcient (Becn1þ / or Map1lc3B /) mice, as well as airway
epithelial cells isolated from these mice, resisted CS-induced cilia
shortening. We identiﬁed the cytosolic deacetylase HDAC6 as a
signaling mediator of autophagy-mediated cilia shortening during
CS exposure [55]. In summary, suppression of the autophagy
pathway in vitro and in vivo improved cilia phenotypes and airway
function during CS exposure.
Recently, we have also shown that CS exposure in epithelial cells
promotes the autophagy-dependent turnover of mitochondria
(mitophagy). In cultured pulmonary epithelial cells, we found that
CS caused mitochondrial dysfunction associated with a decline of
mitochondrial membrane potential, and increased mitochondrial
ROS production [133]. CS induced the mitophagy program through
the stabilization of the mitophagy regulator PINK1. Genetic deﬁ-
ciency of PINK1 protected against CS-induced cell death and mi-
tochondrial dysfunction in vitro. We have also observed in this
model that activation of the mitophagy program can regulate ne-
croptosis, a form of programmed necrosis [133]. Genetic deﬁciency
of PINK1 reduced the phosphorylation of the mixed lineage kinase
domain-like protein (MLKL), a substrate for the receptor-interacting
protein kinase 3 (RIP3) in the necroptosis pathway. The mi-
tochondrial division/mitophagy inhibitor Mdivi-1 also protected
against epithelial cell death in vitro. CS induced epithelial cell death
was reduced by administration of chemical inhibitors of necrosis or
necroptosis. Mitophagy-deﬁcient Pink1/ mice were protected
against mitochondrial dysfunction, airspace enlargement, and mu-
cociliary clearance disruption during CS exposure in vivo. Inhibition
of mitophagy by Mdivi-1 treatment also improved airway pheno-
types in CS-exposed mice in vivo. In human COPD, lung epithelial
cells displayed increased expression of PINK1 and RIP3. These
ﬁndings, taken together, implicate mitophagy in acute airways
dysfunction and in lung emphysematous changes in response to CS
exposure, suggesting that this pathway may represent a therapeutic
target for COPD [133].
Mitophagy may contribute to mitochondrial quality control and
thereby has been predicted to exert a pro-survival role in oxidative
stress [68,134,135]. In the speciﬁc case of CS exposure, a complex
model of toxicant exposure, our results suggest that the activation
of mitophagy may promote the induction of necroptosis, a cell
death program, and also potentially lead to depletion of the
functional mitochondrial pool in the chronic setting [133]. How-
ever, the precise mechanisms by which mitophagy can serve to
promote tissue injury in the CS exposure model remains unclear.
Further studies will be necessary to improve the understanding of
the role of mitophagy in the pathogenesis of COPD.Autophagy, a multifaceted modulator of carcinogenesis and
lung cancer
Autophagy has been recognized as having a complex impact on
the initiation, progression, and treatment of cancer. As a crucial
component of cellular defense mechanisms, autophagy has a pu-
tative anti-carcinogenic effect through the preservation of mi-
tochondria, the clearance of subcellular debris, the recycling of
metabolic precursors, and the dampening of inﬂammation, which
can contribute to genetic instability [136]. Paradoxically, the pro-
survival effects of autophagy may provide a mechanism that
promotes tumor cell survival in established tumors under adverse
conditions, and afford tumor cell resistance to chemotherapeutics,
thus promoting the progression of cancer. In contrast, autophagy
has also been shown to potentiate the lethal effect of che-
motherapeutics through mechanisms dependent on autophagy-
associated cell death [136]. Monoallelic disruption of the Becn1 on
S.W. Ryter, A.M.K. Choi / Redox Biology 4 (2015) 215–225222chromosome 17q21 occurs in human tumors [13]. Abnormal ex-
pression of Beclin 1 in tumor tissue is correlated with poor prog-
nosis and aggressive tumor phenotypes [12,13].
To date, few studies have explored the impact of autophagy
speciﬁcally in lung cancer and therapeutics. Beclin-1 expression
was inversely correlated with tumor size and primary tumor stage
in human lung adenocarcinomas and was reduced in non-small
cell lung carcinoma (NSCLC) relative to normal tissue [137,138].
Induction of autophagy through mTOR inhibitors has been asso-
ciated with radiosensitization in NSCLC cells [139]. The autophagy
inhibitor hydroxychloroquine has been tested for general ther-
apeutic efﬁcacy in NSCLC [14]. Genetic deletion of the autophagy
protein ATG5 results in impaired progression of KRas(G12D)-dri-
ven lung cancer and promotes the survival of tumor bearing mice.
However, the initiation of KRas(G12D)-driven lung tumors in these
mice was accelerated by ATG5 deletion, emphasizing that autop-
hagy may prevent oncogenesis, but promote tumor growth [140].Conclusions and therapeutic implications
It is now clear that autophagy has been associated with pro-
and anti-pathogenic effects in human disease. The potential for
advantageous and deleterious effects of this process in illustrated
in cancer, whereby autophagy can protect against the early stages
of carcinogenesis, yet accelerate tumor growth. In certain diseases
such as sepsis, autophagy may provide a pro-survival advantage by
promoting bacterial clearance, and by modulating inﬂammation.
In cigarette smoke exposure models, we have consistently found
an ampliﬁcation of disease process when autophagy or mitophagy
is activated. To date the arsenal of autophagy modulating ther-
apeutics is mostly limited to experimental compounds. Currently,
only a few compounds that can modulate autophagy have been
evaluated for clinical use, including the mTOR inhibitor rapamycin
(an inducer of autophagy) and chloroquine or hydroxychloroquine
(inhibitors of autophagy). The effectiveness of these compounds in
a given setting may not necessarily exclude off-target effects un-
related to the autophagy pathway. Additional candidate ther-
apeutic compounds that modulate autophagy have been de-
scribed, including Tat-Beclin 1 peptide [141], inhibitors of histone
deacetylases, activators of the AMPK pathway, and Vitamin D
[13,14,142]. The multifaceted effects of autophagy suggest that a
complete understanding of the pathogenic process and the impact
of autophagy would be prudent before attempting to modulate
autophagy in the context of human disease. Furthermore, a better
understanding of the multiple pathways of selective autophagy
and their impact on disease pathogenesis may also facilitate the
design of more speciﬁc therapies for the treatment of pulmonary
diseases, and other related diseases where autophagy may con-
tribute to pathogenesis.Acknowledgments
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